Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21579630 | 0.79 | F12 (1.00) | F12 | |
| SCHEMBL21579806 | 0.78 | F12 (0.73) | F12 | |
| SCHEMBL20179644 | 0.77 | F12 (0.61) | F12 | |
| SCHEMBL21579724 | 0.75 | F12 (1.00) | F12 | |
| SCHEMBL30633270 | 0.75 | F12 (1.00) | F12 | |
| SCHEMBL21579729 | 0.73 | F12 (1.00) | F12 | |
| SCHEMBL21571361 | 0.73 | F12 (1.00) | F12 | |
| SCHEMBL30633180 | 0.73 | F12 (1.00) | F12 | |
| SCHEMBL21571279 | 0.72 | F12 (1.00) | F12 | |
| SCHEMBL30633216 | 0.72 | F12 (1.00) | F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875851-B2 | Factor XIIa inhibitors | F11, F13B, SERPINC1 | F12 4/4885 |
| US-20190352294-A1 | Factor XIIa Inhibitors | F11, F13B, SERPINC1 | F12 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.